Table of Contents Author Guidelines Submit a Manuscript
Journal of Immunology Research
Volume 2018, Article ID 5783639, 10 pages
https://doi.org/10.1155/2018/5783639
Research Article

The Glucagon-Like Peptide-1 Receptor Agonist Exendin-4 Inhibits Lipopolysaccharide-Induced Osteoclast Formation and Bone Resorption via Inhibition of TNF-α Expression in Macrophages

Division of Orthodontics and Dentofacial Orthopedics, Department of Translational Medicine, Tohoku University Graduate School of Dentistry, 4-1 Seiryo-machi, Aoba-ku, Sendai 980-8575, Japan

Correspondence should be addressed to Hideki Kitaura; pj.ca.ukohot.m@aruatikh

Received 27 July 2017; Accepted 24 January 2018; Published 13 March 2018

Academic Editor: Hao Liu

Copyright © 2018 Wei-Ren Shen et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. A. Moayeri, M. Mohamadpour, S. F. Mousavi, E. Shirzadpour, S. Mohamadpour, and M. Amraei, “Fracture risk in patients with type 2 diabetes mellitus and possible risk factors: a systematic review and meta-analysis,” Therapeutics and Clinical Risk Management, vol. Volume 13, pp. 455–468, 2017. View at Publisher · View at Google Scholar · View at Scopus
  2. J. S. Walsh and T. Vilaca, “Obesity, type 2 diabetes and bone in adults,” Calcified Tissue International, vol. 100, no. 5, pp. 528–535, 2017. View at Publisher · View at Google Scholar · View at Scopus
  3. A. Montagnani and S. Gonnelli, “Antidiabetic therapy effects on bone metabolism and fracture risk,” Diabetes, Obesity & Metabolism, vol. 15, no. 9, pp. 784–791, 2013. View at Publisher · View at Google Scholar · View at Scopus
  4. M. T. Bazelier, A. M. Gallagher, T. P. van Staa et al., “Use of thiazolidinediones and risk of osteoporotic fracture: disease or drugs?” Pharmacoepidemiology & Drug Safety, vol. 21, no. 5, pp. 507–514, 2012. View at Publisher · View at Google Scholar · View at Scopus
  5. M. T. Bazelier, P. Vestergaard, A. M. Gallagher et al., “Risk of fracture with thiazolidinediones: disease or drugs?” Calcified Tissue International, vol. 90, no. 6, pp. 450–457, 2012. View at Publisher · View at Google Scholar · View at Scopus
  6. D. J. Betteridge, “Thiazolidinediones and fracture risk in patients with type 2 diabetes,” Diabetic Medicine, vol. 28, no. 7, pp. 759–771, 2011. View at Publisher · View at Google Scholar · View at Scopus
  7. A. V. Schwartz, E. Vittinghoff, D. C. Bauer et al., “Association of BMD and FRAX score with risk of fracture in older adults with type 2 diabetes,” JAMA, vol. 305, no. 21, pp. 2184–2192, 2011. View at Publisher · View at Google Scholar · View at Scopus
  8. P. Vestergaard, L. Rejnmark, and L. Mosekilde, “Relative fracture risk in patients with diabetes mellitus, and the impact of insulin and oral antidiabetic medication on relative fracture risk,” Diabetologia, vol. 48, no. 7, pp. 1292–1299, 2005. View at Publisher · View at Google Scholar · View at Scopus
  9. K. Redlich, S. Hayer, R. Ricci et al., “Osteoclasts are essential for TNF-α-mediated joint destruction,” The Journal of Clinical Investigation, vol. 110, no. 10, pp. 1419–1427, 2002. View at Publisher · View at Google Scholar
  10. S. L. Teitelbaum, “Bone resorption by osteoclasts,” Science, vol. 289, no. 5484, pp. 1504–1508, 2000. View at Publisher · View at Google Scholar · View at Scopus
  11. S. L. Teitelbaum, “Osteoclasts: what do they do and how do they do it?” The American Journal of Pathology, vol. 170, no. 2, pp. 427–435, 2007. View at Publisher · View at Google Scholar · View at Scopus
  12. Y. Azuma, K. Kaji, R. Katogi, S. Takeshita, and A. Kudo, “Tumor necrosis factor-α induces differentiation of and bone resorption by osteoclasts,” The Journal of Biological Chemistry, vol. 275, no. 7, pp. 4858–4864, 2000. View at Publisher · View at Google Scholar · View at Scopus
  13. K. Kobayashi, N. Takahashi, E. Jimi et al., “Tumor necrosis factor α stimulates osteoclast differentiation by a mechanism independent of the ODF/RANKL–RANK interaction,” The Journal of Experimental Medicine, vol. 191, no. 2, pp. 275–286, 2000. View at Publisher · View at Google Scholar · View at Scopus
  14. K. Fuller, C. Murphy, B. Kirstein, S. W. Fox, and T. J. Chambers, “TNFα potently activates osteoclasts, through a direct action independent of and strongly synergistic with RANKL,” Endocrinology, vol. 143, no. 3, pp. 1108–1118, 2002. View at Publisher · View at Google Scholar
  15. H. Kitaura, M. S. Sands, K. Aya et al., “Marrow stromal cells and osteoclast precursors differentially contribute to TNF-α-induced osteoclastogenesis in vivo,” The Journal of Immunology, vol. 173, no. 8, pp. 4838–4846, 2004. View at Publisher · View at Google Scholar
  16. H. Kitaura, P. Zhou, H. J. Kim, D. V. Novack, F. P. Ross, and S. L. Teitelbaum, “M-CSF mediates TNF-induced inflammatory osteolysis,” The Journal of Clinical Investigation, vol. 115, no. 12, pp. 3418–3427, 2005. View at Publisher · View at Google Scholar · View at Scopus
  17. P. Orcel, M. Feuga, J. Bielakoff, and M. C. De Vernejoul, “Local bone injections of LPS and M-CSF increase bone resorption by different pathways in vivo in rats,” The American Journal of Physiology-Endocrinology and Metabolism, vol. 264, 3 Part 1, pp. E391–E397, 1993. View at Publisher · View at Google Scholar
  18. Y. Abu-Amer, F. P. Ross, J. Edwards, and S. L. Teitelbaum, “Lipopolysaccharide-stimulated osteoclastogenesis is mediated by tumor necrosis factor via its P55 receptor,” The Journal of Clinical Investigation, vol. 100, no. 6, pp. 1557–1565, 1997. View at Publisher · View at Google Scholar · View at Scopus
  19. Y. Sakuma, K. Tanaka, M. Suda et al., “Crucial involvement of the EP4 subtype of prostaglandin E receptor in osteoclast formation by proinflammatory cytokines and lipopolysaccharide,” Journal of Bone and Mineral Research, vol. 15, no. 2, pp. 218–227, 2000. View at Publisher · View at Google Scholar
  20. A. L. Dumitrescu, S. Abd-El-Aleem, B. Morales-Aza, and L. F. Donaldson, “A model of periodontitis in the rat: effect of lipopolysaccharide on bone resorption, osteoclast activity, and local peptidergic innervation,” Journal of Clinical Periodontology, vol. 31, no. 8, pp. 596–603, 2004. View at Publisher · View at Google Scholar · View at Scopus
  21. Y. H. Chung, E. J. Chang, S. J. Kim et al., “Lipopolysaccharide from Prevotella nigrescens stimulates osteoclastogenesis in cocultures of bone marrow mononuclear cells and primary osteoblasts,” Journal of Periodontal Research, vol. 41, no. 4, pp. 288–296, 2006. View at Publisher · View at Google Scholar · View at Scopus
  22. N. Bostanci, R. P. Allaker, G. N. Belibasakis et al., “Porphyromonas gingivalis antagonises Campylobacter rectus induced cytokine production by human monocytes,” Cytokine, vol. 39, no. 2, pp. 147–156, 2007. View at Publisher · View at Google Scholar · View at Scopus
  23. H. Kitaura, K. Kimura, M. Ishida, H. Kohara, M. Yoshimatsu, and T. Takano-Yamamoto, “Immunological reaction in TNF-α-mediated osteoclast formation and bone resorption in vitro and in vivo,” Clinical & Developmental Immunology, vol. 2013, article 181849, 8 pages, 2013. View at Publisher · View at Google Scholar · View at Scopus
  24. C. Y. Chiang, G. Kyritsis, D. T. Graves, and S. Amar, “Interleukin-1 and tumor necrosis factor activities partially account for calvarial bone resorption induced by local injection of lipopolysaccharide,” Infection and Immunity, vol. 67, no. 8, pp. 4231–4236, 1999. View at Google Scholar
  25. W. Zou and Z. Bar-Shavit, “Dual modulation of osteoclast differentiation by lipopolysaccharide,” Journal of Bone and Mineral Research, vol. 17, no. 7, pp. 1211–1218, 2002. View at Publisher · View at Google Scholar · View at Scopus
  26. G. P. Garlet, C. R. Cardoso, T. A. Silva et al., “Cytokine pattern determines the progression of experimental periodontal disease induced by Actinobacillus actinomycetemcomitans through the modulation of MMPs, RANKL, and their physiological inhibitors,” Oral Microbiology and Immunology, vol. 21, no. 1, pp. 12–20, 2006. View at Publisher · View at Google Scholar · View at Scopus
  27. M. Mormann, M. Thederan, I. Nackchbandi, T. Giese, C. Wagner, and G. M. Hansch, “Lipopolysaccharides (LPS) induce the differentiation of human monocytes to osteoclasts in a tumour necrosis factor (TNF) α-dependent manner: a link between infection and pathological bone resorption,” Molecular Immunology, vol. 45, no. 12, pp. 3330–3337, 2008. View at Publisher · View at Google Scholar · View at Scopus
  28. T. Kikuchi, T. Matsuguchi, N. Tsuboi et al., “Gene expression of osteoclast differentiation factor is induced by lipopolysaccharide in mouse osteoblasts via Toll-like receptors,” Journal of Immunology, vol. 166, no. 5, pp. 3574–3579, 2001. View at Publisher · View at Google Scholar · View at Scopus
  29. X. Ma, H. Hui, Z. Liu et al., “Poly-GLP-1, a novel long-lasting glucagon-like peptide-1 polymer, ameliorates hyperglycaemia by improving insulin sensitivity and increasing pancreatic beta-cell proliferation,” Diabetes, Obesity & Metabolism, vol. 11, no. 10, pp. 953–965, 2009. View at Publisher · View at Google Scholar · View at Scopus
  30. J. J. Holst, “The physiology of glucagon-like peptide 1,” Physiological Reviews, vol. 87, no. 4, pp. 1409–1439, 2007. View at Publisher · View at Google Scholar · View at Scopus
  31. C. Yamada, Y. Yamada, K. Tsukiyama et al., “The murine glucagon-like peptide-1 receptor is essential for control of bone resorption,” Endocrinology, vol. 149, no. 2, pp. 574–579, 2008. View at Publisher · View at Google Scholar · View at Scopus
  32. B. Nuche-Berenguer, P. Moreno, S. Portal-Nunez, S. Dapia, P. Esbrit, and M. L. Villanueva-Penacarrillo, “Exendin-4 exerts osteogenic actions in insulin-resistant and type 2 diabetic states,” Regulatory Peptides, vol. 159, no. 1-3, pp. 61–66, 2010. View at Publisher · View at Google Scholar · View at Scopus
  33. Y. K. Loke, S. Singh, and C. D. Furberg, “Long-term use of thiazolidinediones and fractures in type 2 diabetes: a meta-analysis,” CMAJ, vol. 180, no. 1, pp. 32–39, 2009. View at Publisher · View at Google Scholar · View at Scopus
  34. R. E. Aubert, V. Herrera, W. Chen, S. M. Haffner, and M. Pendergrass, “Rosiglitazone and pioglitazone increase fracture risk in women and men with type 2 diabetes,” Diabetes, Obesity & Metabolism, vol. 12, no. 8, pp. 716–721, 2010. View at Publisher · View at Google Scholar · View at Scopus
  35. J. P. Bilezikian, R. G. Josse, R. Eastell et al., “Rosiglitazone decreases bone mineral density and increases bone turnover in postmenopausal women with type 2 diabetes mellitus,” The Journal of Clinical Endocrinology & Metabolism, vol. 98, no. 4, pp. 1519–1528, 2013. View at Publisher · View at Google Scholar · View at Scopus
  36. G. Mabilleau, A. Mieczkowska, and D. Chappard, “Use of glucagon-like peptide-1 receptor agonists and bone fractures: a meta-analysis of randomized clinical trials,” Journal of Diabetes, vol. 6, no. 3, pp. 260–266, 2014. View at Publisher · View at Google Scholar · View at Scopus
  37. B. Nuche-Berenguer, P. Moreno, P. Esbrit et al., “Effect of GLP-1 treatment on bone turnover in normal, type 2 diabetic, and insulin-resistant states,” Calcified Tissue International, vol. 84, no. 6, pp. 453–461, 2009. View at Publisher · View at Google Scholar · View at Scopus
  38. P. L. Brubaker, “Incretin-based therapies: mimetics versus protease inhibitors,” Trends in Endocrinology & Metabolism, vol. 18, no. 6, pp. 240–245, 2007. View at Publisher · View at Google Scholar · View at Scopus
  39. J. J. Meier, M. A. Nauck, D. Kranz et al., “Secretion, degradation, and elimination of glucagon-like peptide 1 and gastric inhibitory polypeptide in patients with chronic renal insufficiency and healthy control subjects,” Diabetes, vol. 53, no. 3, pp. 654–662, 2004. View at Publisher · View at Google Scholar · View at Scopus
  40. L. L. Nielsen and A. D. Baron, “Pharmacology of exenatide (synthetic exendin-4) for the treatment of type 2 diabetes,” Current Opinion in Investigational Drugs, vol. 4, no. 4, pp. 401–405, 2003. View at Google Scholar
  41. X. Ma, J. Meng, M. Jia et al., “Exendin-4, a glucagon-like peptide-1 receptor agonist, prevents osteopenia by promoting bone formation and suppressing bone resorption in aged ovariectomized rats,” Journal of Bone and Mineral Research, vol. 28, no. 7, pp. 1641–1652, 2013. View at Publisher · View at Google Scholar · View at Scopus
  42. K. Kimura, H. Kitaura, T. Fujii, Z. W. Hakami, and T. Takano-Yamamoto, “Anti-c-Fms antibody inhibits lipopolysaccharide-induced osteoclastogenesis in vivo,” FEMS Immunology & Medical Microbiology, vol. 64, no. 2, pp. 219–227, 2012. View at Publisher · View at Google Scholar · View at Scopus
  43. J. Saeed, H. Kitaura, K. Kimura et al., “IL-37 inhibits lipopolysaccharide-induced osteoclast formation and bone resorption in vivo,” Immunology Letters, vol. 175, pp. 8–15, 2016. View at Publisher · View at Google Scholar · View at Scopus
  44. M. Pereira, J. Jeyabalan, C. S. Jorgensen et al., “Chronic administration of Glucagon-like peptide-1 receptor agonists improves trabecular bone mass and architecture in ovariectomised mice,” Bone, vol. 81, pp. 459–467, 2015. View at Publisher · View at Google Scholar · View at Scopus
  45. N. Wada, H. Maeda, Y. Yoshimine, and A. Akamine, “Lipopolysaccharide stimulates expression of osteoprotegerin and receptor activator of NF-kappa B ligand in periodontal ligament fibroblasts through the induction of interleukin-1 beta and tumor necrosis factor-alpha,” Bone, vol. 35, no. 3, pp. 629–635, 2004. View at Publisher · View at Google Scholar · View at Scopus